Fish protein hydrolysate (BII-SPH) & health outcomes
Research type
Research Study
Full title
An investigation of blue whiting protein hydrolysate (BII-SPH) supplementation on markers of glycaemic control, metabolic syndrome and appetite in humans
IRAS ID
266643
Contact name
Philip Allsopp
Contact email
Sponsor organisation
Ulster University
Clinicaltrials.gov Identifier
FCBMS-19-062, School of Biomedical Sciences Ethics Filter Committee
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
The association between malnutrition, obesity and type 2 diabetes (T2D) has long been established. Obesity is directly linked to insulin resistance. T2D is now classified as a worldwide epidemic, and effects 100,000 people in Northern Ireland. Physical activity and diet are effective at delaying the onset of T2D although the adherence rate to these are low.
In this research, a total of 60 eligible and consenting participants will be randomly allocated to consume one sachet per day of of flavoured fish protein hydrolysate powder daily (mixed with water) vs control flavoured powder (mixed with water) for a period of 12 weeks.
A fasting blood sample will be taken before and after intervention to determine the effect of the fish protein powder on cholesterol concentrations, lipid profile and inflammation. Blood pressure, stiffness of the arteries and
body shape, size and composition will also be assessed, and some health and lifestyle habits will be captured using questionnaires. An honorarium of £50 will be paid to all participants upon completion of the study to cover their time
and travel costs throughout the 12-week study.REC name
Wales REC 7
REC reference
19/WA/0234
Date of REC Opinion
27 Aug 2019
REC opinion
Favourable Opinion